Hutchison China MediTech
SANET-p trial stopped early for efficacyFutura Medical
Fund raise of £3.25m, at 8p a share, confirmed at EGMScancell
Third collaboration for AvidiMab platformMaxCyte
Increasingly in demand as partner of choiceNexstim
Licensing discussions with academic centre endMereo BioPharma
Additional ASTEROID data supports progressionMereo BioPharma
Oncologie takes global licence to NaviBerGenBio
AXL opportunities opening upMereo BioPharma
Underappreciated and undervaluedNexstim
Making an impression in depression